 | |  | |  | |  | |  | |  | |  | |  | |  | |  |
| The MR archives offer solid proof to the effective and predictive capabilities of our research and analysis. Click any company below to view a full report. |
| An Enviable Track Record The Merriam Report is proud of its remarkable performance and accuracy rate* "Undervalued" stocks generated an average 25.95% profit (a 93% accuracy rate) "Overvalued" stocks declined an average -34.14% (a 92% accuracy rate) *Based on returns generated 3-6 months following date of report for all back-tested and actual investments 1997- June 30, 2010 |
| "The proof is in the pudding" |
MR Quarterly Newsletter Updates
Winter 2010: Major Diversified Chemicals
Our in-depth analysis of the deeply cyclical chemical industry
identified Eastman Chemical (EMN) as a company with
improving earnings quality.
At time of newsletter publication (mid-Jan.), EMN shares
were trading at $60. In Summary Analysis, we advised
readers to consider taking positions in EMN on any pull-back
to the mid $50 area.
On April 22nd, the company reported stellar Q1 results,
blowing consensus estimates right out of the water!
Subscribers of the Merriam Report Quarterly who heeded
our actionable research and analysis, made a potential 25%
profit on EMN as compared to a 14% gain in the S&P 500
(Jan. 29 through April 23).
Newsletter Archives
Spring 2008: A Look at the Drug Stocks
Fall 2008: Consumer Staples & Household Products
Winter 2010: Major Diversified Chemicals
Our in-depth analysis of the deeply cyclical chemical industry
identified Eastman Chemical (EMN) as a company with
improving earnings quality.
At time of newsletter publication (mid-Jan.), EMN shares
were trading at $60. In Summary Analysis, we advised
readers to consider taking positions in EMN on any pull-back
to the mid $50 area.
On April 22nd, the company reported stellar Q1 results,
blowing consensus estimates right out of the water!
Subscribers of the Merriam Report Quarterly who heeded
our actionable research and analysis, made a potential 25%
profit on EMN as compared to a 14% gain in the S&P 500
(Jan. 29 through April 23).
Newsletter Archives
Spring 2008: A Look at the Drug Stocks
Fall 2008: Consumer Staples & Household Products
|
| "MR Rating" is based on our interpretation of the data presented and is provided for informational purposes only. "Results" show changes in the price of a security between the date of report and the subsequent earnings release date. |
| Merriam Report Investment Research Archives |
| Updated on 1-26-13 |
| NEW |
Stocks mentioned in recent articles